TM Owner Merck & Co.
Steglatro 15mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Steglatro 15 mg tablets contain ertugliflozin (as ertugliflozin L-pyroglutamic acid), a sodium-glucose co-transporter 2 (SGLT2) inhibitor manufactured by Merck & Co. It is approved as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus, used alone or added to other glucose-lowering medicines such as metformin, sitagliptin or insulin.
- It is not recommended to improve glycaemic control in type 1 diabetes and is not approved for use in children.
- Steglatro works by causing the kidneys to remove excess glucose in the urine, independent of insulin, and is taken once daily in the morning as either a 5 mg or 15 mg tablet.
- It is a self-administered oral tablet, not a hospital-administered medicine, and US and EU approvals for adults with type 2 diabetes are aligned.
Side Effects
- Steglatro's label carries no boxed warning.
- The most common side effects are genital yeast infections, affecting up to about 12% of women and up to about 4% of men, urinary tract infections in roughly 4%, increased urination and headache.
- More serious but less common reactions that need urgent attention include diabetic ketoacidosis (nausea, vomiting, stomach pain, unusual tiredness and difficulty breathing, which can occur even with near-normal blood sugar), a urinary or genital infection that worsens quickly with fever or feeling unwell (a rare but serious infection called Fournier's gangrene), dehydration and dizziness on standing from volume loss, and any new pain, tenderness, redness or swelling of the leg or foot, which could signal a problem needing urgent review because of a small increased risk of lower-limb amputation.
Precautions & Warnings
- Before and during Steglatro treatment, your healthcare provider checks kidney function; it is not recommended if your eGFR is below 45 mL/min/1.73m2 and should be stopped before major surgery or periods of prolonged fasting because of ketoacidosis risk.
- Steglatro is contraindicated in anyone with a history of serious hypersensitivity to ertugliflozin, and it can cause volume depletion, so use with caution alongside diuretics, in older adults, or with low blood pressure.
- Practise good genital hygiene to reduce yeast infection risk, and do not stop other glucose-lowering medicines abruptly without medical guidance.
- Safety in pregnancy is not established beyond early pregnancy and is generally avoided; discuss contraception and any pregnancy plans with your healthcare provider.
- There is no specific driving restriction, but be alert to symptoms of low or high blood sugar.
Avoid Interactions
- Tell your healthcare provider about all medicines and supplements you take before starting Steglatro.
- Combining it with insulin or insulin-releasing medicines such as sulfonylureas increases the risk of low blood sugar (hypoglycaemia), so a lower dose of the other medicine may be needed.
- Steglatro can lower blood lithium levels, so lithium concentrations should be monitored more closely when starting or stopping treatment.
- Because Steglatro increases glucose in the urine, home urine glucose tests and the 1,5-anhydroglucitol (1,5-AG) blood test become unreliable for monitoring blood sugar control while you take it; use a different monitoring method instead.
- There are no reported food interactions requiring dietary restriction, but avoid becoming dehydrated, and check with your pharmacist before combining with other diabetes or diuretic medicines.
References
Frequently Asked Questions
Steglatro (ertugliflozin) is an SGLT2 inhibitor tablet that helps improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It works by helping the kidneys remove extra glucose in urine and is not approved for type 1 diabetes.
Steglatro is a tablet taken once daily in the morning, with or without food, usually starting at 5 mg and increasing to 15 mg if more blood sugar control is needed. Do not double a missed dose; take the next one at the usual time.
The most common side effects of Steglatro (ertugliflozin) are genital yeast infections and urinary tract infections. Seek urgent care for nausea, vomiting or stomach pain with unusual tiredness (possible diabetic ketoacidosis), or for new leg or foot pain, swelling or redness.
Avoid becoming dehydrated while taking Steglatro (ertugliflozin), and tell your provider before any surgery or fasting procedure, since it should be stopped 4 days beforehand. Combining it with insulin or sulfonylureas raises low blood sugar risk, and lithium levels need closer monitoring.
Steglatro is not recommended if your kidney function (eGFR) is below 45 mL/min/1.73m2, since it works through the kidneys and becomes less effective and less safe as function declines. Your provider checks kidney function before starting and periodically during treatment.
Yes. Steglatro (ertugliflozin) causes glucose to appear in urine as part of how it works, so home urine glucose tests and the 1,5-AG blood test become unreliable for tracking blood sugar. Use blood glucose monitoring or HbA1c instead while taking it.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
